Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (NRIX) Revenue
Annual & quarterly revenue history · segment & region breakdown
NRIX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsNurix Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.07B, an increase of 53.95% year-over-year from $0.08B in FY2025.
Revenue trend
2025 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-11-30 | $0.08B | +$0.03B | +53.95% |
| 2024-11-30 | $0.05B | -$0.02B | -29.15% |
| 2023-11-30 | $0.08B | +$0.04B | +99.31% |
| 2022-11-30 | $0.04B | +$0.01B | +29.84% |
| 2021-11-30 | $0.03B | +$0.01B | +66.95% |
| 2020-11-30 | $0.02B | -$0.01B | -42.73% |
| 2019-11-30 | $0.03B | -$0.01B | -16.91% |
| 2018-11-30 | $0.04B | — | — |
Compare revenue vs peers
BiotechnologyCompare NRIX revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Nurix Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Nurix Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Nurix Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
NRIX revenue · 4 questionsNRIX's trailing twelve-month (TTM) revenue is $0.07B. That is an increase of 53.95% year-over-year from $0.08B in FY2025.
▸ Source: FMP · Nurix Therapeutics, Inc. SEC filings · GAAP · Nurix Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026